Tout sur Martini S.

Quand le VIH résiste à tout, il faut convoquer des molécules de nouvelle génération comme le précise les guidelines internationaux. Tel est le cas de l'ibalizumab qui a fait l'objet d'un poster lors du congrès de Glasgow à propos d'un cas très complexe de multirésistances.

Partner content ViiV Healthcare

Lire l'article

Live from

Lire les articles

Online e-learning

Real-world treatment adherence and strict inclusion criteria used during RCTs can lead to several patient groups being underrepresented. Therefore, real-world data on DTG-based 2DRs are highly needed to be able to evaluate virologic and safety outcomes in these underrepresented patient groups.In this webinar, Dr. Nasreddine highlighted the outcomes of the BREACH DTG-based 2DR cohort, a retrospective, observational, multicenter study (n=10).Subsequently Prof. De Wit, Chair of the Belgian HIV Research Consortium BREACH, gave his clinical implications of these cohort data.Finally, Dr. De Scheerder provided a comprehensive overview of the real-world DTG/3TC data that are currently available beyond Belgium.

Take the course